4th Quarter - Report

TIBER CREEK GROUP for ROIVANT SCIENCES, INC.

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Tene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JAMES HEIMBACH —
JONATHON JONES —
ANDREW MCKECHNIE —
JENNIFER OLSON —
JEFFREY SHAPIRO —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Pharmacy PHA

Issues pertaining to womens health and treatment of endometriosis; Treatment of rare diseases; Issues related to the development of new treatments and therapies; Treatment of Sickle Cell; Gene therapies and treatment of Parkinsons disease

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JAMES HEIMBACH —
JONATHON JONES —
ANDREW MCKECHNIE —
JENNIFER OLSON —
JEFFREY SHAPIRO —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ROIVANT SCIENCES HOLDINGS LTD. United Kingdom United Kingdom — —
ROIVANT SCIENCES LTD. Bermuda Bermuda — —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.